Comparison
SNAP-8 vs. Tesamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Growth
CAS no.
868844-74-0
901758-09-6
Molecular weight
1075.16 g/mol
5135.83 g/mol
Half-life
no data
0.4 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2Mechanism of action
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Tesamorelin
Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
2
of which in humans
1
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2